Scientists wipe out deadly brain tumors in every mouse tested with new cancer therapy

Researchers at UCSF have developed a targeted CAR-T cell therapy that activates only within the brain to treat diffuse midline glioma, a fatal childhood cancer. In mouse models, the treatment successfully eliminated tumors and provided long-term immunity against recurrence.
Why it matters
This therapy offers a potential breakthrough for treating aggressive, previously untreatable brain cancers while minimizing systemic side effects.
Scientists at UC San Francisco have developed a new type of immune cell therapy that activates only after entering the brain, allowing it to attack cancer while remaining inactive elsewhere in the body.
In experiments involving mice, the engineered cells successfully eliminated diffuse midline glioma (DMG), an aggressive childhood brain cancer that spreads into surrounding healthy tissue. The treatment also provided lasting protection. When researchers introduced cancer cells again several weeks later, the immune cells continued fighting and prevented new tumors from developing.
DMG is among the most difficult childhood cancers to treat. It grows into the brainstem, a critical region that regulates breathing, heartbeat, and swallowing. Nearly all children diagnosed with the disease die within a year, and existing treatments have had little success in stopping its progression.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in